COVID-19 Vaccination During Pregnancy Linked to Lower Preeclampsia Risk

Modern research indicates that COVID-19 vaccination during pregnancy, especially with a booster dose, significantly reduces the risk of preeclampsia, a serious pregnancy complication. The findings offer valuable insights into preeclampsia prevention, independent of COVID-19 infection.

Study Details

A multinational study led by researchers from the University of Oxford, published in eClinicalMedicine, analyzed data from 6,527 pregnant women across 18 countries enrolled between 2020 and 2022. Researchers compared vaccinated and unvaccinated women, both with and without SARS-CoV-2 infection, to determine the impact of vaccination status on preeclampsia rates. The study was conducted by the INTERCOVID Consortium. CIDRAP also reported on the study findings.

Key Findings

• COVID-19 infection during pregnancy was associated with a 45% increased risk of preeclampsia. This risk rose to 78% among unvaccinated women. University of Oxford
• Vaccination reduced the overall odds of preeclampsia amongst women receiving a booster dose by 33%, a statistically significant result. University of Oxford
• Among women with pre-existing health conditions such as diabetes, hypertension, or thyroid disorders, vaccination with a booster cut preeclampsia risk by 42%, also statistically significant. University of Oxford
• The protective effect of vaccination remained consistent even after adjusting for key factors, suggesting potential benefits for preeclampsia prevention regardless of infection status. University of Oxford
• Vaccinated women also experienced lower odds of preterm delivery, maternal and perinatal morbidity, and mortality. University of Oxford

Preeclampsia and Vaccination

Preeclampsia is a serious pregnancy complication characterized by high blood pressure and signs of damage to other organ systems, typically developing after 20 weeks of gestation. CIDRAP The study suggests that vaccination may mitigate the risk of preeclampsia, potentially reinforcing current vaccination strategies during pregnancy and providing insights into shared mechanisms between infection-related inflammation and hypertensive disorders of pregnancy.

Further Research

Researchers continue to investigate the underlying mechanisms behind these findings, aiming to better understand the pathophysiology of preeclampsia beyond COVID-19. The study analyzed data from two consecutive cohorts in 2020 and 2022. CIDRAP